Efficacy of Low-Dose Tocilizumab on Relapsing Adult-Onset Still's Disease.


Still's disease is an inflammatory disorder of unknown etiology. First-line therapy is based on corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs) but the frequency of relapses and corticosteroid-induced adverse events are limiting factors. The efficacy of intravenous tocilizumab (TCZ) has been shown at a dose of 8 mg/kg but the… (More)
DOI: 10.14712/18059694.2016.51

1 Figure or Table


  • Presentations referencing similar topics